Alexandria T. Phan, MD, FACP

Publications

• Neuroendocrine Tumors: a Relevant Clinical Update.

  (Rizen EN, Phan AT.) Curr Oncol Rep. 2022 Jun;24(6):703-714 PMID: 35254612 03/08/2022

• Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.

  (Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P, CLARINET Investigators.) Endocrine. 2021 Feb;71(2):502-513 PMID: 33052555 PMCID: PMC7881960 10/15/2020

• Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study.

  (Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM.) Int J Cancer. 2020 Apr 01;146(7):1836-1840 PMID: 31241762 06/27/2019

• Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.

  (Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME, CLARINET Study Group.) Anticancer Drugs. 2020 Mar;31(3):216-222 PMID: 31977567 PMCID: PMC7028287 01/25/2020

• Molecular pathways and targeted therapy in cholangiocarcinoma.

  (Dabney RS, Khalife M, Shahid K, Phan AT.) Clin Adv Hematol Oncol. 2019 Nov;17(11):630-637 PMID: 31851165 12/19/2019

• Immunotherapy and targeted therapy-the new roadmap in cancer treatment.

  (Shahid K, Khalife M, Dabney R, Phan AT.) Ann Transl Med. 2019 Oct;7(20):595 PMID: 31807576 PMCID: PMC6861781 12/07/2019

• Stereotactic body radiation therapy and immunotherapy.

  (Khalife M, Shahid K, Dabney RS, Phan AT.) Clin Adv Hematol Oncol. 2019 Sep;17(9):518-523 PMID: 31549973 09/25/2019

• Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

  (Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI, CLARINET Study Investigators.) Oncologist. 2019 Apr;24(4):463-474 PMID: 30355775 PMCID: PMC6459235 10/26/2018

• BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

  (Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, Lowenthal SP, Vinik AI.) Endocr Pract. 2018 Aug 07 PMID: 30084687 08/08/2018

• Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition.

  (Yu Y, Kong R, Cao H, Yin Z, Liu J, Nan X, Phan AT, Ding T, Zhao H, Wong STC.) Oncotarget. 2018 Jun 15;9(46):27958-27973 PMID: 29963254 PMCID: PMC6021345 07/03/2018

• Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion.

  (Iyer R, Phan AT, Boudreaux JP.) Clin Adv Hematol Oncol. 2017 Apr;15 Suppl 4(4):18-19 PMID: 28654026 06/28/2017

• Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals.

  (Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT.) Clinicoecon Outcomes Res. 2017;9:495-503 PMID: 28860831 PMCID: PMC5566387 09/02/2017